Pilot study with pegylated liposomal doxorubicin for advanced or unresectable hepatocellular carcinoma

We performed a pilot-study on pegylated liposomal doxorubicin (PLD) for advanced hepatocellular carcinoma. Seventeen patients received 40 mg/m(2) PLD intravenously every 4 weeks. A clinical benefit response was achieved in 50% (complete remission 7%, minor remission 7%, stable disease 36%). Toxiciti...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Schmidinger, M, Wenzel, C, Locker, G J, Muehlbacher, F, Steininger, R, Gnant, M, Crevenna, R, Budinsky, A C
Format: Artigo
Jezik:Inglês
Izdano: Nature Publishing Group 2001
Teme:
Regular Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC2364023/
https://ncbi.nlm.nih.gov/pubmed/11747325
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1054/bjoc.2001.2149
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki